New triple therapy trial targets Tough-to-Treat kidney cancers
NCT ID NCT04413123
Summary
This study is testing whether combining three medications—cabozantinib, nivolumab, and ipilimumab—can safely slow the growth of advanced kidney cancer that has spread. The trial will enroll about 60 adults with specific types of non-clear cell kidney cancer that cannot be surgically removed. Researchers will measure how well tumors shrink and how long patients live without their cancer worsening.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02115, United States
-
Brigham & Woman's Hospital
Boston, Massachusetts, 02115, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
UT Southwestern Medical
Dallas, Texas, 75390, United States
Conditions
Explore the condition pages connected to this study.